The Durability and Avidity of MPXV-specific Antibodies Induced by the Two-dose MVA-BN Mpox Vaccine

Author:

Oom Aaron L.,Kottkamp Angelica C.ORCID,Wilson Kesi K.,Yonatan Miilani,Rettig Stephanie,Youn Heekoung Allison,Tuen Michael,Shah Yusra,DuMont Ashley L.,Samanovic Marie I.,Duerr Ralf,Mulligan Mark J.

Abstract

AbstractThe 2022 global outbreak of clade IIb mpox was the first major outbreak of mpox outside of African nations. To control the outbreak, vaccination campaigns were begun using the third-generation orthopoxvirus vaccine MVA-BN. During the vaccination campaign, we launched the New York City Observational Study of Mpox Immunity (NYC OSMI). NYC OSMI is a longitudinal study that enrolled 171 MVA-BN vaccinees with or without prior smallpox vaccination and mpox convalescent individuals. Study participants had blood drawn prior to vaccination, after one dose, and after two doses. Mpox virus (MPXV) neutralizing titers in sera reach a comparable peak in naïve and experienced vaccinees. However, neutralizing titers return to baseline in less than one year for naïve individuals, while remaining elevated in those with prior smallpox vaccination. Both naïve and experienced individuals generate robust, immunodominant IgG responses against MPXV H3 and A35, but with significantly lower avidity in naïve vaccinees. Their vaccinia virus homologs H3 and A33 have previously been shown to be protective targets for orthopoxvirus infection and disease in mouse models. These data highlight a low avidity antibody response elicited by MVA-BN that is short-lived in naïve vaccinees. This study supports the need for studies of long-term protection from MVA-BN, the potential need for booster doses, and further development of next-generation orthopoxvirus vaccines.

Publisher

Cold Spring Harbor Laboratory

Reference48 articles.

1. 2022-23 Mpox (Monkeypox) Outbreak: Global Trends. https://worldhealthorg.shinyapps.io/mpx_global/.

2. 2022 Outbreak Cases and Data | Mpox | Poxvirus | CDC. https://www.cdc.gov/poxvirus/mpox/response/2022/index.html.

3. A Position Statement on Mpox as a Sexually Transmitted Disease;Clinical Infectious Diseases,2023

4. The changing epidemiology of human monkeypox—A potential threat? A systematic review

5. Interim Clinical Considerations for Use of JYNNEOS and ACAM2000 Vaccines during the 2022 U.S. Mpox Outbreak | Mpox | Poxvirus | CDC. https://www.cdc.gov/poxvirus/mpox/clinicians/vaccines/vaccine-considerations.html.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3